



DIVISION OF  
CORPORATION FINANCE

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

May 19, 2021

Ahmed S. Mousa, Esq.  
General Counsel  
Pieris Pharmaceuticals, Inc.  
255 State Street, 9th Floor  
Boston, MA 02109

**Re: Pieris Pharmaceuticals, Inc.**  
**Registration Statement on Form S-3**  
**Filed May 17, 2021**  
**File No. 333-256218**

Dear Mr. Mousa:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Chris Edwards at 202-551-6761 with any questions.

Sincerely,

Division of Corporation Finance  
Office of Life Sciences

cc: Megan N. Gates, Esq.